# Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026
Canonical URL: https://biopharmsignal.com/news/ASND/ascendis-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-7-2026
Ticker: ASND
Company: Ascendis Pharma
Source: Ascendis Pharma
Published: 2026-04-30 20:01 EST
Original Source URL: https://investors.ascendispharma.com
## Summary

COPENHAGEN, Denmark, April 30, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report first quarter 2026 financial results and provide a business update on Thursday, May 7, 2026, before the open of the U.S. financial markets.

## Article Body
COPENHAGEN, Denmark, April 30, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report first quarter 2026 financial results and provide a business update on Thursday, May 7, 2026, before the open of the U.S. financial markets.
## Recent Company News
- 2026-05-07 11:30 EST — [Ascendis Pharma Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/ASND/ascendis-pharma-reports-first-quarter-2026-financial-results) — Source: Ascendis Pharma
- 2026-05-06 20:01 EST — [New 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged ≥5 Years](https://biopharmsignal.com/news/ASND/new-2-year-data-from-pivotal-approach-trial-of-transconr-cnp-navepegritide-show-pronounced-gains-in-growth-outcomes-in-children-with-achondroplasia-aged-5-years) — Source: Ascendis Pharma
- 2026-04-30 20:01 EST — [Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026](https://biopharmsignal.com/news/ASND/ascendis-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-7-2026) — Source: Ascendis Pharma
- 2026-04-21 20:31 EST — [Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028](https://biopharmsignal.com/news/ASND/ascendis-announces-redemption-of-all-575-million-of-outstanding-2-25-convertible-senior-notes-due-2028) — Source: Ascendis Pharma
- 2026-04-20 12:00 EST — [Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq](https://biopharmsignal.com/news/ASND/ascendis-pharma-announces-commencement-of-trading-of-its-ordinary-shares-on-nasdaq) — Source: Ascendis Pharma
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)